{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:55:28Z","timestamp":1775458528547,"version":"3.50.1"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Immune-related adverse events have been frequently reported using immune checkpoint inhibitors. However, these reports are commonly observed in single-organ toxicity. Thus, the compound, multiple, multisite, and multi-organ toxicities are seldom recognized and lack treatment experience, finally leading to severe challenges in the clinical treatment of such patients. More case studies are needed to fully understand the diagnostic and treatment strategies formulti-organ immune-related adverse events. This report aims to share the clinical diagnosis and treatment experience of a patient with nasopharyngeal carcinoma who developed severe hepatitis and rash after treatment with toripalimab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 57-year-old male farmer was diagnosed with nasopharyngeal carcinoma. Ten days after treatment with the first cycle of terprilizumab combined with gemcitabine and cisplatin, the patient was admitted to the hospital for abnormal liver function tests. Two days after admission, the patient developed another rash.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Based on the patient\u2019s past history, medication history, personal history, and relevant laboratory and imaging examinations, the liver injury and rash for this patient is probable caused by toripalimab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient received methylprednisolone sodium succinate injection for anti-inflammatory, tiopronin and magnesium isoglycyrrhizate for hepatoprotective, fluticasone propionate cream and cetirizine for anti-allergic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient\u2019s hepatitis and rash were effectively controlled after treatment, and no reoccurrence was observed during subsequent antitumor therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case proposes that clinician should comprehensively determine the risk of adverse reactions and strengthen medication monitoring to ensure patient safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000044122","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T19:01:29Z","timestamp":1756494089000},"page":"e44122","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Diagnosis and treatment of a patient with severe hepatitis and rash caused by toripalimab: A case report"],"prefix":"10.1097","volume":"104","author":[{"given":"Wei","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Sichuan Shehong People\u2019s Hospital, Shehong, Suining, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sichuan Shehong People\u2019s Hospital, Shehong, Suining, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4535-3207","authenticated-orcid":false,"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Clinical Medical College and The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sichuan Shehong People\u2019s Hospital, Shehong, Suining, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sichuan Shehong People\u2019s Hospital, Shehong, Suining, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4392-5631","authenticated-orcid":false,"given":"Ting","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Clinical Medical College and The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260406","doi-asserted-by":"crossref","first-page":"1071983","DOI":"10.3389\/fimmu.2023.1071983","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors.","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front Immunol"},{"key":"R2-20260406","doi-asserted-by":"crossref","first-page":"1504142","DOI":"10.3389\/fonc.2024.1504142","article-title":"The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies.","volume":"14","author":"Imani","year":"2024","journal-title":"Front Oncol"},{"key":"R3-20260406","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: an Anti-CTLA-4 antibody for metastatic melanoma.","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R4-20260406","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41571-021-00597-8","article-title":"Harnessing big data to characterize immune-related adverse events.","volume":"19","author":"Jing","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R5-20260406","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1177\/1060028015586218","article-title":"Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.","volume":"49","author":"Barbee","year":"2015","journal-title":"Ann Pharmacother"},{"key":"R6-20260406","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review.","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"R7-20260406","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/s12885-019-5785-z","article-title":"The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1\/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis.","volume":"19","author":"Gu","year":"2019","journal-title":"BMC Cancer"},{"key":"R8-20260406","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ijc.32132","article-title":"A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors.","volume":"145","author":"Arnaud Coffin","year":"2019","journal-title":"Int J Cancer"},{"key":"R9-20260406","first-page":"490","article-title":"Difficult issues in management of immunotherapy-related toxicity for cancer patients.","volume":"37","author":"Yaping","year":"2022","journal-title":"J Pract Oncol"},{"key":"R10-20260406","first-page":"8812983","article-title":"A severe case of drug-induced liver injury after gemcitabine administration: a highly probable causality grading as assessed by the updated RUCAM diagnostic scoring system.","volume":"2020","author":"Mascherona","year":"2020","journal-title":"Case Rep Hepatol"},{"key":"R11-20260406","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1023\/A:1026514527313","article-title":"A fatal case of cholestatic liver failure probably related to gemcitabine.","volume":"11","author":"Coeman","year":"2000","journal-title":"Ann Oncol"},{"key":"R12-20260406","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1385\/MO:20:4:385","article-title":"Gemcitabine and reactivation of hepatitis B.","volume":"20","author":"Cheong","year":"2003","journal-title":"Med Oncol"},{"key":"R13-20260406","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000058524","article-title":"Single-agent gemcitabine is active in previously treated metastatic breast cancer.","volume":"60","author":"Spielmann","year":"2001","journal-title":"Oncology (Huntingt)"},{"key":"R14-20260406","first-page":"2067","article-title":"Literature analysis of adverse reactions caused by toripalimab.","volume":"31","author":"Jian-Qun","year":"2022","journal-title":"Chin J New Drugs"},{"key":"R15-20260406","first-page":"9","article-title":"Research progress of immune checkpoint inhibitor mediated hepatotoxicity.","volume":"9","author":"Haojie","year":"2023","journal-title":"J Compr Oncol Ther Electron Ed"},{"key":"R16-20260406","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3390\/cancers16040795","article-title":"The ABC of immune-mediated hepatitis during immunotherapy in patients with cancer: from pathogenesis to multidisciplinary management.","volume":"16","author":"Lasagna","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R17-20260406","doi-asserted-by":"crossref","first-page":"100170","DOI":"10.1016\/j.jhepr.2020.100170","article-title":"Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors.","volume":"2","author":"De Martin","year":"2020","journal-title":"JHEP Rep"},{"key":"R18-20260406","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"R19-20260406","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R20-20260406","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"R21-20260406","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3390\/biomedicines10040790","article-title":"Review of immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC)-their incidence, management, multiorgan irAEs, and rechallenge.","volume":"10","author":"Vaddepally","year":"2022","journal-title":"Biomedicines"},{"key":"R22-20260406","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13181-021-00833-8","article-title":"A review of cancer immunotherapy toxicity: immune checkpoint inhibitors.","volume":"17","author":"Chhabra","year":"2021","journal-title":"J Med Toxicol"},{"key":"R23-20260406","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients.","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res Treat"},{"key":"R24-20260406","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00002018-200831010-00003","article-title":"Methods for causality assessment of adverse drug reactions: a systematic review.","volume":"31","author":"Agbabiaka","year":"2008","journal-title":"Drug Saf"},{"key":"R25-20260406","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/jocd.13763","article-title":"Dermatologic adverse reactions to proton-pump inhibitors: a synthetized review.","volume":"20","author":"Salloum","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"R26-20260406","first-page":"55","article-title":"Analysis and countermeasures of adverse reactions induced by methylprednisolone sodium succinate for injection in 55 children.","volume":"20","author":"Fei","year":"2023","journal-title":"China Licensed Pharm"},{"key":"R27-20260406","first-page":"577","article-title":"Expert consensus on the clinical application of platinum drugs and the management of adverse reactions.","volume":"29","year":"2019","journal-title":"Pharm Today"},{"key":"R28-20260406","first-page":"176","article-title":"Adverse reactions of gemcitabine and its prevention.","volume":"5","author":"Hongbin","year":"2003","journal-title":"Adverse Drug React J"},{"key":"R29-20260406","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaad.2008.01.001","article-title":"Chemotherapeutic agents and the skin: an update.","volume":"58","author":"Heidary","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R30-20260406","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1200\/JCO.1996.14.5.1743","article-title":"Maculopapular rashes secondary to gemcitabine injection for non-small-cell lung cancer.","volume":"14","author":"Chen","year":"1996","journal-title":"J Clin Oncol"},{"key":"R31-20260406","first-page":"1244","article-title":"Clinical observation and care of gemcitabine drug-induced rash.","volume":"26","author":"Xia","year":"2011","journal-title":"West China Med J"},{"key":"R32-20260406","doi-asserted-by":"crossref","first-page":"6805","DOI":"10.3390\/curroncol30070498","article-title":"Molecular mechanisms of cutaneous immune-related adverse events (irAEs) induced by immune checkpoint inhibitors.","volume":"30","author":"Teng","year":"2023","journal-title":"Curr Oncol"},{"key":"R33-20260406","doi-asserted-by":"crossref","first-page":"1147513","DOI":"10.3389\/falgy.2023.1147513","article-title":"Mucocutaneous adverse events to immune checkpoint inhibitors.","volume":"4","author":"Muhaj","year":"2023","journal-title":"Front Allergy"},{"key":"R34-20260406","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial.","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"key":"R36-20260406","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN Clinical Practice Guidelines in Oncology.","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R38-20260406","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study.","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"R39-20260406","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/cen.14405","article-title":"Evaluating tertiary adrenal insufficiency in rheumatology patients on long-term systemic glucocorticoid treatment.","volume":"94","author":"Sagar","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R40-20260406","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.wneu.2016.01.033","article-title":"Association of steroid use with deep venous thrombosis and pulmonary embolism in neurosurgical patients: a national database analysis.","volume":"89","author":"Lieber","year":"2016","journal-title":"World Neurosurg"},{"key":"R41-20260406","doi-asserted-by":"crossref","first-page":"664809","DOI":"10.3389\/fonc.2021.664809","article-title":"Immune-related multiple-organs injuries following ICI treatment with tislelizumab in an advanced non-small cell lung cancer patient: a case report.","volume":"11","author":"Deng","year":"2021","journal-title":"Front Oncol"},{"key":"R42-20260406","doi-asserted-by":"crossref","first-page":"799077","DOI":"10.3389\/fimmu.2021.799077","article-title":"Case report: glucocorticoid effect observation in a ureteral urothelial cancer patient with ICI-associated myocarditis and multiple organ injuries.","volume":"12","author":"Hu","year":"2021","journal-title":"Front Immunol"},{"key":"R43-20260406","doi-asserted-by":"crossref","first-page":"730320","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: a systemic review and meta-analysis.","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"R44-20260406","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/CJI.0000000000000337","article-title":"Safety of immunotherapy rechallenge after immune-related adverse events in patients with advanced cancer.","volume":"44","author":"Kartolo","year":"2021","journal-title":"J Immunother"},{"key":"R45-20260406","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer.","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:00:50Z","timestamp":1775455250000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":43,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044122","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"2025-02-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}